• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Clinical implications from the European Heart Rhythm Association consensus document on antiarrhythmic drug therapy.欧洲心律协会抗心律失常药物治疗共识文件的临床意义
Anatol J Cardiol. 2018 Jul;20(1):48-51. doi: 10.14744/AnatolJCardiol.2018.03285.
2
Lessons from the current European Heart Rhythm Association consensus document on screening for atrial fibrillation.当前欧洲心律协会关于房颤筛查的共识文件中的经验教训。
Anatol J Cardiol. 2018 Mar;19(3):222-224. doi: 10.14744/AnatolJCardiol.2018.37043.
3
Antiarrhythmic drugs management in patients with atrial fibrillation: the new guidelines.心房颤动患者的抗心律失常药物管理：新指南
Minerva Cardioangiol. 2011 Apr;59(2):187-95.
4
Current practice of antiarrhythmic drug therapy for prevention of atrial fibrillation in Europe: The European Heart Rhythm Association survey.目前在欧洲预防心房颤动的抗心律失常药物治疗实践：欧洲心律协会调查。
Europace. 2013 Apr;15(4):478-81. doi: 10.1093/europace/eut063.
5
Electropharmacological effects of antiarrhythmic drugs on atrial fibrillation termination. Part II: New insights into the electrophysiological mechanisms of atrial fibrillation termination.抗心律失常药物对心房颤动转复的电药理学效应。第二部分：心房颤动转复电生理机制的新见解。
Ital Heart J. 2003 Jul;4(7):442-7.
6
Drug therapy for termination of atrial fibrillation and maintenance of sinus rhythm.用于终止心房颤动并维持窦性心律的药物治疗。
Can J Cardiol. 2005 Sep;21 Suppl B:19B-25B.
7
Antithrombotic Therapy in Atrial Fibrillation Associated with Valvular Heart Disease: Executive Summary of a Joint Consensus Document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE).心房颤动伴瓣膜性心脏病的抗栓治疗：欧洲心律协会（EHRA）和欧洲心脏病学会血栓工作组的联合共识文件的执行摘要，得到 ESC 瓣膜性心脏病工作组、南非心脏协会（SA Heart）、心律学会（HRS）、亚太心律学会（APHRS）、心脏心律失常学会（Cardiac Arrhythmia Society of Southern Africa，CASSA）和拉丁美洲心脏刺激和电生理学会（SOLEACE）的认可。
Thromb Haemost. 2017 Dec;117(12):2215-2236. doi: 10.1160/TH-17-10-0709. Epub 2017 Dec 6.
8
Antiarrhythmic drugs for atrial fibrillation: focus on dronedarone.用于心房颤动的抗心律失常药物：聚焦于决奈达隆
Expert Rev Cardiovasc Ther. 2009 May;7(5):473-81. doi: 10.1586/erc.09.14.
9
[Current antiarrhythmic drug therapy in atrial fibrillation].[心房颤动的当前抗心律失常药物治疗]
Dtsch Med Wochenschr. 2010 Mar;135 Suppl 2:S33-7. doi: 10.1055/s-0030-1249206. Epub 2010 Mar 10.
10
New pharmacological approaches to atrial fibrillation.心房颤动的新药理学方法。
Drug Discov Today. 2012 Jul;17(13-14):654-9. doi: 10.1016/j.drudis.2012.02.007. Epub 2012 Feb 20.

引用本文的文献

1
Establishing Safe Working Parameters for Radiofrequency Ablation In Vitro Using Acoustic Sensing, Probability Mapping, and Catheter Contact Angle.利用声学传感、概率映射和导管接触角建立体外射频消融的安全工作参数
J Innov Card Rhythm Manag. 2022 Jul 15;13(7):5087-5099. doi: 10.19102/icrm.2022.130703. eCollection 2022 Jul.

本文引用的文献

1
Antiarrhythmic drugs-clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP).抗心律失常药物——临床应用与临床决策：欧洲心律协会（EHRA）和欧洲心脏病学会（ESC）心血管药理学工作组的共识文件，得到心律学会（HRS）、亚太心律学会（APHRS）和国际心血管药物治疗学会（ISCP）认可。
Europace. 2018 May 1;20(5):731-732an. doi: 10.1093/europace/eux373.
2
New directions in antiarrhythmic drug therapy for atrial fibrillation.心房颤动抗心律失常药物治疗的新方向
Future Cardiol. 2013 Jan;9(1):71-88. doi: 10.2217/fca.12.78.
3
Cost-benefit and cost-savings analyses of antiarrhythmic medication monitoring.抗心律失常药物监测的成本效益和成本节约分析。
Am J Health Syst Pharm. 2012 Sep 15;69(18):1569-73. doi: 10.2146/ajhp110270.
4
Intravenous administration of flecainide or propafenone in patients with recent-onset atrial fibrillation does not predict adverse effects during 'pill-in-the-pocket' treatment.静脉给予氟卡尼或普罗帕酮治疗新近发生的心房颤动患者，不能预测“口袋药物”治疗期间的不良效应。
Heart. 2010 Apr;96(7):546-9. doi: 10.1136/hrt.2009.187963.
5
Pathophysiology and pharmacology of the cardiac "late sodium current.".心脏“晚钠电流”的病理生理学与药理学
Pharmacol Ther. 2008 Sep;119(3):326-39. doi: 10.1016/j.pharmthera.2008.06.001. Epub 2008 Jul 1.
6
Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.β受体阻滞剂、胺碘酮联合β受体阻滞剂或索他洛尔预防植入式心律转复除颤器电击的比较：OPTIC研究：一项随机试验。
JAMA. 2006 Jan 11;295(2):165-71. doi: 10.1001/jama.295.2.165.
7
K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients.《K/DOQI 透析患者心血管疾病临床实践指南》
Am J Kidney Dis. 2005 Apr;45(4 Suppl 3):S1-153.
8
Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation.缓释普罗帕酮（propafenone SR）用于心房颤动患者的疗效与安全性。
Am J Cardiol. 2003 Oct 15;92(8):941-6. doi: 10.1016/s0002-9149(03)00974-3.
9
Antiarrhythmic drug initiation in patients with atrial fibrillation.心房颤动患者抗心律失常药物的起始治疗
Prog Cardiovasc Dis. 1999 Jul-Aug;42(1):75-90. doi: 10.1016/s0033-0620(99)70010-1.
10
A classification of antiarrhythmic actions reassessed after a decade of new drugs.在十年新药研发之后重新评估的抗心律失常作用分类。
J Clin Pharmacol. 1984 Apr;24(4):129-47. doi: 10.1002/j.1552-4604.1984.tb01822.x.

欧洲心律协会抗心律失常药物治疗共识文件的临床意义

Clinical implications from the European Heart Rhythm Association consensus document on antiarrhythmic drug therapy.

作者信息

Özcan Emin Evren, Görenek Bülent

机构信息

Department of Cardiology, Faculty of Medicine, Eskişehir Osmangazi University; Eskişehir-Turkey.

出版信息

Anatol J Cardiol. 2018 Jul;20(1):48-51. doi: 10.14744/AnatolJCardiol.2018.03285.

DOI:10.14744/AnatolJCardiol.2018.03285
PMID:29952363
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6237798/
Abstract

The recently published consensus document by the European Heart Rhythm Association presents a patient-tailored pharmacological antiarrhythmic treatment approach targeting the arrhythmia mechanism. This document comprehensively reviews the indications, side effects, and contraindications of antiarrhythmic drugs. In this paper, we reviewed novel treatment concepts offered by the consensus document.

摘要

欧洲心律协会最近发表的共识文件提出了一种针对心律失常机制的个体化药物抗心律失常治疗方法。该文件全面回顾了抗心律失常药物的适应证、副作用和禁忌证。在本文中，我们回顾了该共识文件提出的新治疗理念。